Orient Europharma Co Ltd (4120) Fair Value & Analysis

Healthcare · TW · Market cap 3.9B TWD

Below-average quality, and screening another 76% overvalued on our models.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case (13.25 TWD). The favourable scenario is already priced in.
• Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.

How to read this chart

60‑month range 27.70 TWD – 53.29 TWD · fair‑value band 10.70 TWD – 13.25 TWD · the 47.90 TWD price screens above the 11.71 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Orient Europharma Co Ltd (4120) currently trades at 47.90 TWD, while our model-based Fair Value estimate is 11.71 TWD, implying the stock looks roughly 75.6% overvalued today. The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Orient Europharma Co Ltd generated revenue of 4.6B TWD at a net margin of -9.6%. Revenue declined 0.5% year over year. It earns a return on equity of -5.4%. Net debt stands at 986M TWD. Fundamentals as of Aug 22, 2026

Our scenario range runs from 10.70 TWD (bear case) to 13.25 TWD (bull case); at 47.90 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 19% below its 52-week high and 12% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -76%, 4120 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based (48.56 TWD) versus Dividend Discount (11.15 TWD). Highest evidence: Gordon GGM (70).

Key figures & financial health

Quality Score breakdown

About the company

Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include weight management, andrology, cardiovascular, respiratory, neurology, cardiovascular, metabolism, obstetrics and gynecology, antibiotic, immunology, and anti-cancer drugs.

Full company description

Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include weight management, andrology, cardiovascular, respiratory, neurology, cardiovascular, metabolism, obstetrics and gynecology, antibiotic, immunology, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplements for liquid nutrition, regular blood lipids, L-arginines, agile movements, and improved sleep qualities under the Nutrifuel brand name. In addition, the company offers dermo and cosmetic products under the Cumlaude Labs, AGLabs, Bio-Oil, and ISISPHARMAs brand names. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trial. Orient EuroPharma Co., Ltd. was incorporated in 1982 and is based in Taipei, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Orient Europharma Co Ltd reported revenue of 4.6B TWD in FY2025 versus 4.8B TWD in FY2021, a compound −0.9%/yr. Reported net income was −567M TWD in FY2025.

4120 screens 76% overvalued. Compare with Sun Pharmaceutical Industries Limited →

Peer Group

Drug Manufacturers - Specialty & Generic · 639 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.